CCTG

MAC.15 | RxPONDER

NCT01272037

MAC.15

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Status:

Closed to Accrual

26459-200.png

III

Phase

Line of Therapy.png

Adjuvant

Line of Therapy

Disease Stage.png

Early Cancer

Disease Stage

Target.png

Biomarker(s)

ER+, HER2-

Investigational

Product

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane

Treatment Arms

o Experimental: Arm II (endocrine therapy)

o Experimental: Arm I (chemotherapy and endocrine therapy)